Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cgbio Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, indicating that each pending matter is handled by a different individual. The portfolio involves 1 distinct art unit, suggesting a unified technical classification for these filings.
HUANG, GIGI GEORGIANA is identified as the busiest examiner for the company, currently overseeing 1 pending office action. This examiner is one of the 2 distinct examiners engaged with the portfolio. The 2 pending office actions are concentrated within 1 distinct art unit, which may streamline the prosecution strategy within Biotechnology & Pharmaceuticals.
The involvement of 2 distinct examiners for 2 pending office actions means there is no overlap in personnel across the current cases. HUANG, GIGI GEORGIANA handles 1 pending office action, while the other action is assigned elsewhere. Practitioners can focus their analysis on the 1 distinct art unit to understand the specific standards applied to the company's Biotechnology & Pharmaceuticals applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
| TSAY, MARSHA M | 1 | 45.7% | +52.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18816354 | COMPOSITION COMPRISING DRYING METHOD-APPLIED FIBROUS ACELLULAR DERMAL MATRIX AND METHOD FOR PREPARING SAME | HUANG, GIGI GEORGIANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18816354 | COMPOSITION COMPRISING DRYING METHOD-APPLIED FIBROUS ACELLULAR DERMAL MATRIX AND METHOD FOR PREPARING SAME | HUANG, GIGI GEORGIANA | — |
| 18836345 | PHARMACEUTICAL COMPOSITIONS FOR HEMOSTASIS AND WOUND HEALING IN GASTROINTESTINAL TRACT | TSAY, MARSHA M | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18816354 | COMPOSITION COMPRISING DRYING METHOD-APPLIED FIBROUS ACELLULAR DERMAL MATRIX AND METHOD FOR PREPARING SAME | HUANG, GIGI GEORGIANA | 1611 | §102§103 | Non-Final OA | — | Pending | Aug 27, 2024 |
| 18836345 | PHARMACEUTICAL COMPOSITIONS FOR HEMOSTASIS AND WOUND HEALING IN GASTROINTESTINAL TRACT | TSAY, MARSHA M | — | §103 | Final Rejection | — | Pending | Aug 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial